Overcoming absolute dysphagia in a thirty-year-old patient with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report
Frontiers in Oncology · 28.05.2026 · 16
DOI: 10.3389/fonc.2026.1840539 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 28.05.2026. Verfasst von Luca Carlofrancesco Ammoni und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, Azienda Socio-Sanit…. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Dysphagie
Abstract (Originalsprache)
Background
Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) accounts for approximately 3–7% of all NSCLCs and predominantly affects young, never-smoker patients. Lorlatinib, a third-generation ALK tyrosine kinase inhibitor (TKI), has demonstrated significant efficacy as first-line therapy. However, its exclusive oral formulation poses a challenge in patients with dysphagia. Case presentation We report the case of a 30-year-old woman with metastatic ALK-positive NSCLC who presented with severe dysphagia due to bulky supraclavicular and laterocervical lymphadenopathy compressing the cervical oesophagus. Given the impossibility of swallowing, lorlatinib 100 mg daily was administered via a nasogastric tube after tablet crushing. Within days, rapid reduction of cervical lymph node swelling was observed, swallowing improved, and the patient resumed oral intake. Imaging performed two weeks later showed partial response; at six months, PET-CT demonstrated complete metabolic response.
Discussion
This case supports the feasibility and effectiveness of lorlatinib administration via the enteral route in patients unable to swallow. Despite the lack of formal evidence for alternative formulations, pharmacokinetic data suggest adequate absorption.
Conclusion
Crushed lorlatinib administered through a nasogastric tube represents a practical and effective option for dysphagic patients with ALK-positive NSCLC requiring early target-directed therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, Azienda Socio-Sanitaria Territoriale (ASST) Spedali Civili, Brescia, Italy.
Zitieren
APA
Ammoni, L. C., Carola, G., Ippolito, G., Baggi, A., Consoli, F., Esposito, A., Pedrazzini, I., Berruti, A., & Grisanti, S. (2026). Overcoming absolute dysphagia in a thirty-year-old patient with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1840539
Vancouver
Ammoni LC, Carola G, Ippolito G, Baggi A, Consoli F, Esposito A, et al. Overcoming absolute dysphagia in a thirty-year-old patient with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1840539
BibTeX
@article{Ammoni2026,
author = {Ammoni, Luca Carlofrancesco and Carola, Giorgia and Ippolito, Giuseppe and Baggi, Alice and Consoli, Francesca and Esposito, Andrea and Pedrazzini, Ilaria and Berruti, Alfredo and Grisanti, Salvatore},
title = {Overcoming absolute dysphagia in a thirty-year-old patient with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1840539}
}
EUVIMED